81 filings
Page 4 of 5
6-K
xv560i8g4348ta270x
4 Jan 23
Current report (foreign)
4:35pm
6-K
t7p6hp0xjoevzl5yrlm
3 Jan 23
Current report (foreign)
9:12am
6-K
bguybgksec085qym7
30 Dec 22
Interim Results for the Six Months Ending 30 September 2022
6:04am
6-K
dzhgngqzkhtvsu yn
22 Dec 22
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
6:05am
6-K
bevgwl3t tx
21 Dec 22
Current report (foreign)
6:02am
6-K
df614mylcf4
6 Dec 22
OKYO publicly files a registration statement with the SEC
7:00am
6-K
m5u628nbvh9
1 Dec 22
Current report (foreign)
7:00am
6-K
2th3lb 5w
25 Nov 22
Current report (foreign)
6:01am
6-K
exyc i50l
21 Nov 22
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
6:15am
6-K
uqed9jt2pon p4q8g9
10 Nov 22
Current report (foreign)
6:04am
6-K
8f7nnx1cw trla
24 Oct 22
Current report (foreign)
7:00am
6-K
lgq8wmz0rd8kn39 12
20 Oct 22
OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference
7:00am
6-K
76h z86k7cj
8 Sep 22
Current report (foreign)
10:37am
6-K
zo5bv1ci0 t43
7 Sep 22
Result of Annual General Meeting
10:20am
6-K
kfgf4omdsjc1m
30 Aug 22
Current report (foreign)
6:04am
6-K
e31hd7
19 Aug 22
Current report (foreign)
6:05am
6-K
123lu8v e4d309
16 Aug 22
Final audited results for the year ended 31 March 2022
6:23am
6-K
ohml7n8fyfo 9x
9 Jun 22
Current report (foreign)
7:00am
6-K
b11c yh0euy
20 May 22
Current report (foreign)
6:10am
6-K
ucz2jpwyw6u42hnbd5n8
19 May 22
Current report (foreign)
12:23pm